Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters?

Journal of Clinical Psychopharmacology

Volumn 32, Issue 1, 2012, Pages 110-113

  Reist, Christopher ^a,b,c   Wu, Joseph C ^c   Lilja, Ylva ^c   Mukherjee, Jogeshwar ^c   Gripeos, Dimitrios ^a   Constantinescu, Cristian ^c   Raggi, Maria Augusta ^d   Mercolini, Laura ^d   Ozdemir, Vural ^e  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b Education   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

BCRP; blood brain barrier; drug drug interaction; ketoconazole; membrane transporters; P glycoprotein; treatment resistant psychiatric illness

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DOPAMINE 2 RECEPTOR; FALLYPRIDE F 18; FEXOFENADINE; FLUORINE 18; GLYCOPROTEIN P; KETOCONAZOLE; PALIPERIDONE; RISPERIDONE; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CASE REPORT; CORPUS STRIATUM; DRUG RECEPTOR BINDING; DRUG TRANSPORT; HUMAN; HYPOPHYSIS; MALE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR OCCUPANCY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ADULT; ANTI-ALLERGIC AGENTS; ANTIPSYCHOTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BINDING, COMPETITIVE; BLOOD-BRAIN BARRIER; CORPUS STRIATUM; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, INTRAMUSCULAR; KETOCONAZOLE; MALE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PITUITARY GLAND; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; TERFENADINE;

EID: 84855342164     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182408fc8     Document Type: Article

References (24)

1. Ozdemir V, Lerer B. Pharmacogenomics and the promise of personalized medicine. In: Kalow W, Meyer UA, Tyndale RF, eds. Pharmacogenomics, Second Expanded Edition. New York, NY: Francis & Taylor; 2005, 13-50
2. Ozdemir V, Kalow W, Okey AB, et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and CY9A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol. 2001;21:603-607. (Pubitemid 33116661)
3. Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999;147:300-305. (Pubitemid 30010551)
4. Pacchioni AM, Gabriele A, Donovan JL, et al. P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats. Int J Neuropsychopharmacol. 2010;13(8):1067-1077.
5. Ozdemir V, Godard B. Crossing the blood-brain-barrier: integration of scientific innovation with socio-ethical reflection. Psychiatric Times. 2007;24(10):1-3.
6. Aravagiri M, Yuwiler A, Marder SR. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (Berl). 1998;139:356-363. (Pubitemid 28435032)
7. Wang JS, Ruan Y, Taylor RM, et al. The brain penetration of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol. 2004;7:415-419. (Pubitemid 39648071)
8. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33:165-174. (Pubitemid 40023528)
9. Zhang M, Ballard ME, Pan L, et al. Lack of cataleptogenic potentiation with non-imidazole H(3) receptor antagonists reveals potential drug-drug interactions between imidazole-based H(3) receptor antagonists and antipsychotic drugs. Brain Res. 2005;1045:142-149. (Pubitemid 40725230)
10. Kharasch ED, Walker A, Hoffer C, et al. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. J Clin Pharmacol. 2005;45:79-88.
11. Wang Z, Hamman MA, Huang SM, et al. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther. 2002;71:414-420. (Pubitemid 34701348)
12. Mercolini L, Grillo M, Bartoletti C, et al. Simultaneous analysis of classical neuroleptics, atypical antipsychotics and their metabolites in human plasma. Anal Bioanal Chem. 2007;388(1):235-243. (Pubitemid 46712512)
13. Miura M, Uno T, Tateishi T, et al. Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography. J Pharm Biomed Anal. 2007;43(2):741-745. (Pubitemid 44960560)
14. Nakagami T, Yasui-Furukori N, Saito M, et al. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005;78(1):43-51. (Pubitemid 40956930)
15. Cooray HC, Blackmore CG, Maskell L, et al. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport. 2002;13(16):2059-2063. (Pubitemid 36005925)
16. Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci. 2007;96(12):3226-3235.
17. Zhang W, Mojsilovic-Petrovic J, Andrade MF, et al. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 2003;17(14):2085-2087.
18. Jung SM, Kim KA, Cho HK, et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005;78(5):520-528. (Pubitemid 41698906)
19. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999;359(2):147-151. (Pubitemid 29142884)
20. Jovanovi N, Boina N, Lovri M, et al. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naBve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol. 2010;66(11):1109-1117.
21. Ozdemir V, Suarez-Kurtz G, Stenne R, et al. Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. OMICS. 2009;13(1):43-62.
22. Ozdemir V, Knoppers BM. From government to anticipatory governance: responding to challenges set by emerging technologies and innovation. In: Kickbusch I, ed. Governance for Health in the 21st Century. New York: Springer. In press.
23. Ommer R,Wynne B, Downey R, et al. Pathways to Integration. Genome British Columbia GSEAC Subcommittee on Pathways to Integration. Vancouver: Genome BC; 2011.
24. Owen R, Goldberg N. Responsible innovation: a pilot study with the U.K. Engineering and Physical Sciences Research Council. Risk Anal. 2010;30:1699-1707.